美國東部時間2022年05月07日上午09：33(MT Newwires)--Orchestra BioMed和Health Science Acquirements Corp.2(HSAQ)周二表示，他們已經達成合並協議。
熱門資訊> 正文
Orchestra BioMed，Health Science收購公司合併；合併后的公司將在納斯達克上市
2022-07-05 21:34
- Health Sciences Acquisitions(HSACU) 0
- HEALTH SCIENCES ACQUISITIONS CORP 2(HSAQ) 0
- Health Sciences Acquisitions(HSAC) 0
09:33 AM EDT, 07/05/2022 (MT Newswires) -- Orchestra BioMed and Health Sciences Acquisitions Corp. 2 (HSAQ) said Tuesday they have entered into a merger agreement.
The shares of the combined company -- Orchestra BioMed Holdings -- will be listed on Nasdaq under the ticker "OBIO."
合併后的公司--樂團生物醫藥控股公司--的股票將在納斯達克上市，股票代碼是「OBIO」。
The companies said the deal will provide a minimum of $70 million in gross proceeds to the combined company at closing and up to $160 million if there are no redemptions by Health Sciences shareholders. The combined company is expected to have a pro forma market cap of $407 million assuming no redemptions.
兩家公司表示，這筆交易完成后，將為合併后的公司提供至少7000萬美元的毛收入，如果Health Science的股東沒有贖回，毛收入將高達1.6億美元。假設沒有贖回，合併后的公司預計預計市值將達到4.07億美元。
Orchestra BioMed also said it has closed a $110 million Series D financing and that the combined company is expected to get a minimum of $180 million in gross proceeds from the merger and financing. The combined company is expected to have enough capital to fund operations into 2026.
Orchestra BioMed還表示，它已經完成了1.1億美元的D系列融資，合併后的公司預計將從合併和融資中獲得至少1.8億美元的毛收入。合併后的公司預計將有足夠的資本為2026年的運營提供資金。
The merger is expected to close in Q4 of 2022.
合併預計將於2022年第四季度完成。
Price: 9.99, Change: +0.01, Percent Change: +0.1
價格：9.99，變化：+0.01，變化百分比：+0.1
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
